Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

• Publication date: February 2012

Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Liposarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Liposarcom...

Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Liposarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Liposarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Liposarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Liposarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Liposarcoma Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Liposarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Liposarcoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Liposarcoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Liposarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Liposarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Liposarcoma Therapeutics market landscape? – Identify, understand and capitalize.

Therapy Industry in the United Kingdom

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Liposarcoma Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Subtypes of Liposarcoma 7
2.2 Epidemiology 10
2.3 Etiology 10
2.4 Symptoms 10
2.5 Prognosis 11
2.6 Staging 11
2.6.1 Stage I 11
2.6.2 Stage II-III 11
2.6.3 Stage IV (metastatic) 11
2.7 Survival Rate 11
2.8 Risk Factors for Liposarcoma 12
2.9 Diagnosis 12
2.9.1 Biopsy 12
2.9.2 Computerized Tomography (CT) scan 12
2.9.3 Magnetic Resonance Imaging (MRI) 12
2.9.4 Positron Emission Tomography (PET) scan 12
2.9.5 X-ray 12
2.10 Treatment of Liposarcoma 12
2.10.1 Surgery 12
2.10.2 Radiation 13
2.10.3 Chemotherapy 13
2.10.4 First-line therapy (The US, Europe and Japan) 14
2.10.5 Second-line therapy (The US, Europe and Japan) 14
2.10.6 Approved second-line/ third-line therapy in Europe 15
2.11 GlobalData Pipeline Report Guidance 16
3 Liposarcoma Therapeutics - Market Characterization 17
3.1 Liposarcoma Therapeutics Market Size (2006-2011) - Global 17
3.2 Liposarcoma Therapeutics Market Forecast (2011-2019) - Global 19
3.3 Liposarcoma Therapeutics Market Size (2006-2011) - the US 21
3.4 Liposarcoma Therapeutics Market Forecast (2011-2019) - the US 22
3.5 Liposarcoma Therapeutics Market Size (2006-2011) - the UK 23
3.6 Liposarcoma Therapeutics Market Forecast (2011-2019) –the UK 24
3.7 Liposarcoma Therapeutics Market Size (2006-2011) - France 25
3.8 Liposarcoma Therapeutics Market Forecast (2011-2019) - France 26
3.9 Liposarcoma Therapeutics Market Size (2006-2011) - Germany 27
3.10 Liposarcoma Therapeutics Market Forecast (2011-2019) - Germany 28
3.11 Liposarcoma Therapeutics Market Size (2006-2011) - Italy 29
3.12 Liposarcoma Therapeutics Market Forecast (2011-2019) - Italy 30
3.13 Liposarcoma Therapeutics Market Size (2006-2011) - Spain 31
3.14 Liposarcoma Therapeutics Market Forecast (2011-2019) - Spain 32
3.15 Liposarcoma Therapeutics Market Size (2006-2011) - Japan 33
3.16 Liposarcoma Therapeutics Market Forecast (2011-2019) - Japan 34
3.17 Drivers and Barriers for Liposarcoma 35
3.17.1 Drivers for the Liposarcoma Therapeutics Market 35
3.17.2 Barriers for the Liposarcoma Therapeutics Market 36
3.18 Opportunity and Unmet Needs 37
3.19 Key Takeaway 37
4 Liposarcoma Therapeutics Market - Competitive Assessment 38
4.1 Overview 38
4.1.1 Strategic Competitor Assessment 38
4.2 Product Profiles for the Major Products in Liposarcoma 39
4.2.1 Yondelis (trabectedin, ET-743) 39
4.2.2 Doxorubicin 40
4.2.3 Ifosfamide 41
4.3 Key Takeaway 41
5 Liposarcoma Therapeutics - Pipeline Assessment 42
5.1 Overview 42
5.2 Strategic Pipeline Assessment 42
5.3 Pipeline Analysis by Phase of Development 43
5.3.1 Liposarcoma Therapeutics - Pre- registration 43
5.3.2 Liposarcoma Therapeutics - Phase III Pipeline 44
5.3.3 Liposarcoma Therapeutics - Phase II Pipeline 44
5.3.4 Liposarcoma Therapeutics - Phase I/II Pipeline 45
5.3.5 Liposarcoma Therapeutics - Phase I Pipeline 45
5.4 Liposarcoma Therapeutics - Pipeline by Mechanism of Action 46
5.5 Liposarcoma Therapeutics - Other Promising Mechanisms of Actions 47
5.6 Technology Trends Analytic Framework 48
5.7 Liposarcoma Therapeutics– Promising Drugs under Clinical Development 49
5.8 Molecule Profile for Drugs under Phase III Clinical Development 50
5.8.1 Ridaforolimus 50
5.8.2 TH-302 52
5.9 Key Takeaway 53
6 Liposarcoma Therapeutics - Clinical Trials Mapping 54
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 54
6.2 Clinical Trials by Phase 55
6.3 Clinical Trials by Trial Status 56
6.4 Prominent Sponsors 57
6.5 Top Sponsors Participating in Liposarcoma Therapeutics Clinical Trials 59
7 Liposarcoma Therapeutics - Strategic Assessment 60
7.1 Future Market Competition Scenario 60
8 Liposarcoma Therapeutics - Future Players 61
8.1 Introduction 61
8.2 Company Profiles for the Marketed and Promising Drugs 61
8.2.1 Ariad Pharmaceuticals 61
8.2.2 Merck & Co. Inc. 63
8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C 65
8.2.4 PharmaMar S.A. 65
8.2.5 Threshold Pharmaceuticals 66
8.2.6 Merck Serono 67
8.3 Other Companies in the Liposarcoma Market, 2011 68
9 Liposarcoma Therapeutics - Licensing and Partnership Deals 69
10 Liposarcoma Therapeutics - Appendix 70
10.1 Market Definitions 70
10.2 Abbreviations 70
10.3 Methodology 71
10.3.1 Coverage 72
10.3.2 Secondary Research 72
10.3.3 Forecasting 72
10.3.4 Primary Research 74
10.3.5 Expert Panel Validation 75
10.4 Contact Us 75
10.5 Disclaimer 75
10.6 Bibliography 75

List of Tables

Table 1: Recurrence in subtypes of liposarcoma 8
Table 2: Incidence of liposarcoma in Major Markets in 2011 10
Table 3: Five year survival rates for subtypes of liposarcoma 11
Table 4: Surgical resection in liposarcoma 13
Table 5: First-line therapy treatment for liposarcoma in G7 14
Table 6: Second-line therapy treatment for liposarcoma in G7 14
Table 7: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 17
Table 8: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019 19
Table 9: Liposarcoma Therapeutics Market, the US, Revenue($m), 2006-2011 21
Table 10: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 22
Table 11: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 23
Table 12: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 24
Table 13: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 25
Table 14: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 26
Table 15: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 27
Table 16: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m),2011-2019 28
Table 17: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Table 18: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 30
Table 19: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
Table 20: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 32
Table 21: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 33
Table 22: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 34
Table 23: Efficacy of trabectedin 40
Table 24: Comparison of Yondelis adverse events with doxorubicin and ifosfamide 40
Table 25: Liposarcoma Therapeutics - Pre-registration, 2011 43
Table 26: Liposarcoma Therapeutics - Phase III Pipeline, 2011 44
Table 27: Liposarcoma Therapeutics - Phase II Pipeline, 2011 44
Table 28: Liposarcoma Therapeutics - Phase I/II Pipeline, 2011 45
Table 29: Liposarcoma Therapeutics - Phase I Pipeline, 2011 45
Table 30: Liposarcoma Therapeutics - Other Promising Mechanisms of Actions 47
Table 31: Liposarcoam Therapeutics– Promising Drugs Under Clinical Development, 2011 49
Table 32: Patients characteristics in SUCCEED trial 50
Table 33: PFS observed in SUCCEED trial 51
Table 34: Adverse Events observed during SUCCEED trial 51
Table 35: Adverse events observed with the class of mTOR inhibitors 51
Table 36: Responses shown by soft tissue sarcoma group in TH-302 Phase II study 53
Table 37: Adverse events of TH-302 53
Table 38: Hematologic Toxicity shown by TH-302 53
Table 39: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011 54
Table 40: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011 55
Table 41: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011 56
Table 42: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011 57
Table 43: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 58
Table 44: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011 59
Table 45: Ariad Pharmaceuticals - Liposarcoma Pipeline Product, 2011 62
Table 46: Merck & Co. - Liposarcoma Pipeline Product, 2011 64
Table 47: Threshold Pharmaceuticals Inc. - Liposarcoma Pipeline Product, 2011 66
Table 48: Merck Serono - LiposarcomaTherapeutics Pipeline 67
Table 49: Liposarcoma Therapeutics - Future Players, 2011 68
Table 50: Liposarcoma Therapeutics, Global, Deals 69

List of Figures

Figure 1: Characteristics of subtypes of liposarcoma 7
Figure 2: Percentage split of subtypes of liposarcoma 8
Figure 3: Yondelis treatment pathway as second/third line therapy 15
Figure 4: Liposarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011 17
Figure 5: Liposarcoma Therapeutics , Market Share (%), 2011 18
Figure 6: Liposarcoma Therapeutics Market, Global, Market Forecast ($m), 2011-2019 19
Figure 7: Liposarcoma Therapeutics, Market Share (%), 2019 20
Figure 8: Liposarcoma Therapeutics Market, the US, Revenue ($m), 2006-2011 21
Figure 9: Liposarcoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 22
Figure 10: Liposarcoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 23
Figure 11: Liposarcoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 24
Figure 12: Liposarcoma Therapeutics Market, France, Revenue ($m), 2006-2011 25
Figure 13: Liposarcoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 26
Figure 14: Liposarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 27
Figure 15: Liposarcoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 28
Figure 16: Liposarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Figure 17: Liposarcoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 30
Figure 18: Liposarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
Figure 19: Liposarcoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 32
Figure 20: Liposarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 33
Figure 21: Liposarcoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 34
Figure 22: Liposarcoma Therapeutics - Drivers and Barriers, 2011 36
Figure 23: Opportunity and Unmet Need in Liposarcoma Therapeutics Market, 2011 37
Figure 24: Strategic Competitor Assessment of Liposarcoma Therapeutics Market, 2011 38
Figure 25: Liposarcoma Therapeutics Pipeline by Phase of Clinical Development, 2011 43
Figure 26: Liposarcoma Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 46
Figure 27: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline, 2011 48
Figure 28: Technology Trends Analytic Framework of the Liposarcoma Therapeutics Pipeline - Description, 2011 49
Figure 29: Response shown by liposaroma patients in TH-302 Phase II study 52
Figure 30: Liposarcoma Therapeutics - Clinical Mapping by Region / Country, 2011 54
Figure 31: Liposarcoma Therapeutics - Clinical Mapping by Phase, 2011 55
Figure 32: Liposarcoma Therapeutics - Clinical Mapping by Trial Status, 2011 56
Figure 33: Liposarcoma Therapeutics - Clinical Mapping by Overall Sponsors, 2011 57
Figure 34: Liposarcoma Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 58
Figure 35: Liposarcoma Therapeutics - Clinical Mapping by Top Sponsors, 2011 59
Figure 36: Liposarcoma Therapeutics - Implications for Future Market Competition, 2011 60
Figure 37: Liposarcoma Therapeutics - Clinical Pipeline by Company, 2011 61
Figure 38: GlobalData Market Forecasting Model 74

Companies mentioned
Ariad Pharmaceuticals
Merck & Co. Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
PharmaMar S.A.
Threshold Pharmaceuticals
Merck Serono